PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 30, 2024Brain and Behavior5 citationsOpen Access

Escalating to medium‐ versus high‐efficacy disease modifying therapy after low‐efficacy treatment in relapsing remitting multiple sclerosis

View Full Paper
JMJannis MüllerIRIzanne RoosTKTomáš Kalinčík

Key Points

Key points are not available for this paper at this time.

Abstract

In patients with relapsing remitting multiple sclerosis (RRMS) on low-efficacy disease modifying therapies (DMT), the optimal strategy on how to escalate treatment once needed, remains unknown.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Müller et al. (2024) studied this question.

synapsesocial.com/papers/68e6cbf0b6db643587649cechttps://doi.org/10.1002/brb3.3498
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immortal time bias in observational studies of drug effects2007 · 587 citations
  2. 2Confounding by Indication in Epidemiologic Studies of Commonly Used Analgesics2002 · 179 citations
  3. 3Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients2021 · 15 citations
  4. 4Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database2017 · 79 citations
  5. 5Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study2013 · 10 citations